Ricardo C Aguiar

US Patent:

7112420, Sep 26, 2006

Filed:

Sep 19, 2001

Appl. No.:

09/957635

Inventors:

Margaret A. Shipp - Wellesley MA, US
Ricardo Aguiar - Chestnut Hill MA, US
Liqun Gu - Plainsboro NJ, US
Kunihiko Takeyama - Newton MA, US

Assignee:

Dana-Farber Cancer Institute - Boston MA

International Classification:

C12N 15/00
C12N 15/85
C12N 15/63
C07H 21/04

US Classification:

435 696, 4353201, 435325, 4352523, 43525411, 536 235, 536 245

Abstract:

The invention provides isolated nucleic acids molecules, designated BBAP nucleic acid molecules, which encode proteins that interact with or bind to BAL molecules, which are differentially expressed in non-Hodgkin's lymphoma. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing BBAP nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a BBAP gene has been introduced or disrupted. The invention still further provides isolated BBAP proteins, fusion proteins, antigenic peptides and anti-BBAP antibodies. Diagnostic methods using compositions of the invention are also provided.

US Patent:

7632660, Dec 15, 2009

Filed:

May 9, 2005

Appl. No.:

11/125015

Inventors:

Margaret A. Shipp - Wellesley MA, US
Ricardo Aguiar - Chestnut Hill MA, US
Liqun Gu - Plainsboro MA, US
Kunihiko Takeyama - Newton MA, US

Assignee:

Dana-Farber Cancer Institute, Inc. - Boston MA

International Classification:

C12P 21/00
C07K 14/00
C07H 21/04

US Classification:

435 691, 530350, 514 2

Abstract:

The invention provides isolated nucleic acids molecules, designated BBAP nucleic acid molecules, which encode proteins that interact with or bind to BAL molecules, which are differentially expressed in non-Hodgkin's lymphoma. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing BBAP nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a BBAP gene has been introduced or disrupted. The invention still further provides isolated BBAP proteins, fusion proteins, antigenic peptides and anti-BBAP antibodies. Diagnostic methods using compositions of the invention are also provided.

US Patent:

7858742, Dec 28, 2010

Filed:

Aug 16, 2004

Appl. No.:

10/918877

Inventors:

Margaret Shipp - Wellesley MA, US
Ricardo Aguiar - Chestnut Hill MA, US
Yoshi Yakushijin - Matsuyama, JP

Assignee:

Dana-Farber Cancer Institute - Boston MA

International Classification:

C07K 14/00
C07H 21/00
C12P 21/00
C12N 15/63

US Classification:

530350, 536 231, 435 71, 514 44

Abstract:

The invention provides isolated nucleic acids molecules, designated BAL nucleic acid molecules, which are differentially expressed in non-Hodgkin's lymphoma. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing BAL nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a BAL gene has been introduced or disrupted. The invention still further provides isolated BAL proteins, fusion proteins, antigenic peptides and anti-BAL antibodies. Diagnostic methods using compositions of the invention are also provided.

US Patent:

6870040, Mar 22, 2005

Filed:

Oct 29, 1999

Appl. No.:

09/830762

Inventors:

Margaret Shipp - Wellesley MA, US
Ricardo Aguiar - Chestnut Hill MA, US
Yoshi Yakushijin - Ehime, JP

Assignee:

Dana-Farber Cancer Institute - Boston MA

International Classification:

C07H021/04

US Classification:

536 235, 514 44, 536 231, 536 243, 536 2431

Abstract:

The invention provides isolated nucleic acids molecules, designated BAL nucleic acid molecules, which are differentially expressed in non-Hodgkin's lymphoma. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing BAL nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a BAL gene has been introduced or disrupted. The invention still further provides isolated BAL proteins, fusion proteins, antigenic peptides and anti-BAL antibodies. Diagnostic methods using compositions of the invention are also provided.